Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 129

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 129
---
 (see Note 13 to the accompanying consolidated financial statements), could result in additional limitations
on the Company’s post-merger net operating loss carryforwards. Consequently, even if the Company achieves profitability, it may
not be able to utilize a material portion of PTSC’s, or the post-merger Company’s net operating loss carryforwards and other
tax attributes, which could have a material adverse effect on cash flow and results of operations.

Risks Related
to Our Dependence on Third Parties 

Future development collaborations may be important
to us. If we are unable to enter into or maintain these collaborations, or if these collaborations are not successful, our business could
be adversely affected. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, we may in the future determine to seek to collaborate with pharmaceutical and biotechnology companies
for the development of product candidates. We may face significant competition in seeking appropriate collaborators. Our ability to reach
a definitive agreement for any collaboration will depend, among other things, upon our assessment of the collaborator’s resources
and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of
factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have
to curtail the development of a potential product candidate, reduce or delay its development program or one or more of our other potential
development programs, delay its potential development schedule or reduce the scope of research activities, or increase our expenditures
and all development activities at our own expense. If we fail to enter into collaborations and do not have sufficient funds or expertise
to undertake the necessary development activities, we may not be able to further develop any potential future product candidates, and
our business may be materially and adversely affected.

If any future potential collaboration does not result
in the successful development of products or product candidates, product candidates could be delayed, and we may need additional resources
to develop product candidates. All of the risks relating to product development, regulatory approval and commercialization described in
this periodic report also apply to the activities of our collaborators.

We may contract with third parties for the manufacture
of product candidates for preclinical and clinical studies and may expect to continue to do so for commercialization. This potential reliance
on third parties increases the risk that we will not have sufficient quantities of product candidates or products at an acceptable cost
and quality, which could delay, prevent